Pharmesis International Ltd.
5 Kallang Sector
#03-02
Singapore 349279
Company registration no.: 200309641E

PROFIT GUIDANCE FOR THE GROUP'S UNAUDITED FINANCIAL RESULTS FOR SECOND QUARTER AND HALF YEAR ENDED 30 JUNE 2019

The Board of Directors (the "**Board**") of Pharmesis International Ltd. (the "**Company**", and together with its subsidiaries, collectively the "**Group**") wishes to announce that after preliminary assessment of the Group's unaudited financial results for the second quarter ("**2QFY2019**") and half year ended 30 June 2019 ("**1HFY2019**"), the Board would like to advise that the Group is expected to report a net loss for 2QFY2019 and 1HFY2019.

The expected net loss was mainly attributed to lower sales during the 2QFY2019 and 1HFY2019.

Further details of the Group's financial performance will be disclosed when the Company announces its unaudited financial results for 2QFY2019 and 1HFY2019.

The Board wishes to advise its shareholders and investors to exercise caution when dealing with the shares of the Company. Shareholders and investors should consult with their stock brokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions that they should take.

BY ORDER OF THE BOARD

Wu Xuedan
Executive Director and Chief Executive Officer
1 August 2019